Huvepharma announced that it has acquired the global rights for the full OptiPhos brand, product and registrations from Enzyvia. Both companies produce feed additives.
OptiPhos is an E. coli 6-phytase, first marketed in 2006 in the U.S. and now sold in 47 countries around the world.
The addition of the global rights of OptiPhos will extend Huvepharma's existing enzyme business. Huvepharma previously marketed and distributed OptiPhos as a partner of Enzyvia for different countries in the Middle East, Europe, Africa and Asia.
Along with the OptiPhos brand, all related patents, intellectual property, trademarks, global regulatory registrations and production assets are included in this transaction.
"With this acquisition, Huvepharma has realized an integrated global sales, marketing and production organization for its leading phytase and xylanase brands. These brands are sold under the Optiphos and Hostazym brands around the world. Huvepharma is dedicated to develop further its enzyme range to provide the most effective nutritional value to its customers around the world," says Ir. Karel Bierman, global product manager enzymes for Huvepharma.
